| Pyr10 |
1315323-00-2 |
1315323-00-2 |
| N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide |
N-(4-氯-3-吡啶基)-4-[(2,2-二氟-1,3-苯并二恶茂-5-基)甲基]-1-哌嗪甲酰胺 |
1346528-50-4 |
| 1-(2-iodoethyl)-2-methyl-5-nitro-imidazole |
1-(2-碘乙基)-2-甲基-5-硝基-1H-咪唑 |
16156-90-4 |
| Antidesmone |
ANTIDESMONE |
222629-77-8 |
| 2-Chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino]-2-hydroxypropoxy]benzonitrile hydrochloride |
2-氯-6-[(2R)-3-[[1,1-二甲基-2-(2-萘基)乙基]氨基]-2-羟基丙氧基]苯腈盐酸盐 |
324523-20-8 |
| A2AR-agonist-1 |
A2AR-AGONIST-1 |
41552-95-8 |
| MonoMethyl auristatin E |
一甲基澳瑞他汀 E |
474645-27-7 |
| (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide |
(2R)-3-环戊基-2-[4-(甲基磺酰基)苯基]-N-(噻唑-2-基)丙酰胺 |
300353-13-3 |
| N-(3-Bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine |
N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺 |
300842-64-2 |
| 1-Ethyl (2R,4S)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl][5-(3-carboxypropoxy)-2-pyrimidinyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2H)-quinolinecarboxylate |
(2R,4S)-4-[[[3,5-双(三氟甲基)苯基]甲基][5-(3-羧丙氧基)-2-嘧啶基]氨基]-2-乙基-3,4-二氢-6-(三氟甲基)-1(2H)-喹啉羧酸乙酯 |
866399-87-3 |
| Atomoxetine EP Impurity A |
托莫西汀EP杂质A |
873310-33-9 |
| BI-3812 |
CPD1815 |
2166387-64-8 |
| Glenzocimab |
GLENZOCIMAB (格仑西单抗 ) |
2101829-58-5 |
| Relfovetmab |
RELFOVETMAB (瑞弗维单抗 ) |
2171034-70-9 |
| Budigalimab |
Budigalimab |
2098225-93-3 |
| Amatuximab |
阿麦妥单抗 |
931402-35-6 |
| Iladatuzumab |
Iladatuzumab |
1906205-76-2 |
| Foralumab |
FORALUMAB ( 福雷芦单抗 ) |
946415-64-1 |
| Lesofavumab |
Lesofavumab |
1807960-57-1 |
| Pepinemab |
PEPINEMAB (派比奈单抗 ) |
2097151-87-4 |
QQ
微信
